Nevertheless, while CCL5 became a more dominant ligand for CCR5 in the KPC-4545 tumor (Table S1), CCL4 remained a dominant ligand for CCR5 and CXCL12, CXCL10, and CXCL16 arose as major ligands for different receptors in the KPC-3403 model following anti-IL-1β treatment (Table S2). The gene discussed is CCR5; the disease is neoplasm.